Esophageal Carcinoma Clinical Trial
Official title:
Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy
The purpose of this study is to test the drug bevacizumab in combination with cetuximab. Because this combination has not been tested in cancer patients before, results will be analyzed to see what effects the combination of bevacizumab with cetuximab has on esophageal cancer.
Cancer of the esophagus often has a poor outcome since many patients have advanced disease
when they are diagnosed. The average survival rate after five years has increased from 4% in
the 1970s to around 14% currently.
Surgery to remove the tumor or treatment with radiotherapy alone has led to disappointing
results for patients. Chemotherapy has some activity in patients with advanced disease,
although responses are usually short. New strategies are trying to combine these three
treatment approaches to improve survival for these patients.
This study will test the combination of cetuximab and bevacizumab in patients with locally
advanced esophageal cancer. This is a group of patients with usually poor outcomes from
treatment with surgery, radiotherapy or chemotherapy alone. Scientifically, this study will
help assess the value in combining these two different types of drug.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02355249 -
Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer
|
Phase 3 | |
| Completed |
NCT01691625 -
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer
|
N/A | |
| Not yet recruiting |
NCT05937438 -
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05777707 -
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02527057 -
Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer
|
N/A | |
| Recruiting |
NCT06009705 -
Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
|
||
| Recruiting |
NCT04652180 -
Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .
|
N/A | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 | |
| Recruiting |
NCT06199895 -
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
|
Phase 2 | |
| Completed |
NCT00590031 -
Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
|
Phase 2 | |
| Active, not recruiting |
NCT00176800 -
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
|
Phase 2 | |
| Completed |
NCT03099382 -
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04607590 -
Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
|
||
| Recruiting |
NCT00991094 -
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
|
||
| Completed |
NCT01855854 -
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
|
Phase 2 | |
| Recruiting |
NCT06265285 -
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
|
Phase 2 | |
| Recruiting |
NCT05795595 -
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1/Phase 2 |